AptarGroup is about to release earnings. Ponder this Bear Case Scenario:
Some pharmaceutical companies have taken drug delivery development in-house. As the trend intensifies, it will result in dropping demand for Aptar’s pharmaceutical products. in the mean time cash flow from this product supports an investment grade rating.
There have been many dispensing innovations in the consumer products fields. Many feel we have reached the peak and not much is left for now. Sop where will the growth come from.
Aerosol Sprays have generated wrath from regulators, environmentalists and consumer advocates. They aren’t finished yet and will continue to attack the spray.
George Gutowski writes from a caveat emptor perspective.